NeuroThera Labs Advances Phase IIb Tourette Trial With Key Manufacturing Milestone - TipRanks

NeuroThera Labs has completed manufacturing and secured European batch release for SCI-110, enabling shipments for its FDA-approved Phase IIb trial in adults with Tourette Syndrome. Site initiation has been finalized at clinical centers in the U.S., Germany, and Israel, allowing the company to begin enrolling patients and strengthening its position in CNS therapeutics.

Read at Google News (dyspraxia, dyscalculia, Tourette)

All articles from 6 November 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.